# VenEx (NCT04267081)

> Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04267081
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Helsinki University Central Hospital
- Conditions: Acute Myeloid Leukemia
- Interventions: Venetoclax
- Enrollment: 104
- Primary outcome: Complete remission (CR)/complete remission rate with incomplete hematologic recovery (CRi) rate in study cohort after three cycles.

## Indexed commentary on VenEx so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=venex-nct04267081